Aliases & Classifications for Ureteral Disease

Aliases & Descriptions for Ureteral Disease:

Name: Ureteral Disease 12 14
Ureteral Diseases 42 69
Ureteral Disorders 41
Disorder of Ureter 69

External Ids:

Disease Ontology 12 DOID:1426
MeSH 42 D014515
NCIt 47 C27148
UMLS 69 C0041954

Summaries for Ureteral Disease

MedlinePlus : 41 your kidneys make urine by filtering wastes and extra water from your blood. the urine travels from the kidneys to the bladder in two thin tubes called ureters. the ureters are about 8 to 10 inches long. muscles in the ureter walls tighten and relax to force urine down and away from the kidneys. small amounts of urine flow from the ureters into the bladder about every 10 to 15 seconds. sometimes the ureters can become blocked or injured. this can block the flow of urine to the bladder. if urine stands still or backs up the ureter, you may get a urinary tract infections. doctors diagnose problems with the ureters using different tests. these include urine tests, x-rays, and examination of the ureter with a scope called a cystoscope. treatment depends on the cause of the problem. it may include medicines and, in severe cases, surgery. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Ureteral Disease, also known as ureteral diseases, is related to vesicoureteral reflux and vibratory urticaria. An important gene associated with Ureteral Disease is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are TGF-Beta Pathway and p70S6K Signaling. The drugs Tamsulosin and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include testes, kidney and the ureter, and related phenotypes are cardiovascular system and growth/size/body region

Disease Ontology : 12 A urinary system disease that is located in the ureter.

Related Diseases for Ureteral Disease

Diseases related to Ureteral Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
id Related Disease Score Top Affiliating Genes
1 vesicoureteral reflux 10.8
2 vibratory urticaria 10.3 SMAD2 SMAD3 TGFB1
3 speech and communication disorders 10.3 SMAD2 SMAD3 TGFB1
4 upper respiratory tract disease 10.3 CTGF SMAD2 TGFB1
5 hereditary night blindness 10.3 CTGF SMAD3 TGFB1
6 rhinitis 10.2 PAX2 SMAD2 SMAD3
7 ulnar hemimelia 10.2 BMP7 CTGF SMAD2
8 hypotrichosis simplex 10.2 ACE REN
9 congenital pulmonary airway malformation 10.2 PAX2 REN
10 lubani-al saleh-teebi syndrome 10.2 SMAD3 SMAD7 TGFB1
11 albinism, oculocutaneous, type ia 10.2 CCL2 CTGF TGFB1
12 albright's hereditary osteodystrophy 10.2 SMAD2 SMAD3 SMAD7
13 lymphoblastic lymphoma 10.2 AQP2 CTGF REN TGFB1
14 agammaglobulinemia 6 10.1 ACE CTGF TGFB1
15 hyperinsulinemic hypoglycemia, familial, 3 10.1 ACE REN
16 flat umbilicus familial 10.1 ACE REN TGFB1
17 renal tubular acidosis 10.1 CCL2 CTGF SMAD3 TGFB1
18 uterine inflammatory disease 10.1 REN SERPINE1
19 demyelinating polyneuropathy 10.1 AQP2 BMP7 TGFB1
20 leber congenital amaurosis 10.1 SMAD2 SMAD3 SMAD7 TGFB1
21 myopia 10.1 ACE AQP2 REN
22 carbohydrate metabolic disorder 10.1 ACE REN
23 aorta angiosarcoma 10.1 ACE AQP2 REN
24 mixed germ cell-sex cord neoplasm 10.1 ACE REN TGFB1
25 detrusor sphincter dyssynergia 10.1 CCL2 SMAD2 TGFB1
26 skin conditions 10.1 ACE CCL2 TGFB1
27 aortic aneurysm, familial thoracic 6 10.1 CCL2 CTGF SMAD2 SMAD3 TGFB1
28 benign secondary hypertension 10.0 CCL2 SERPINE1 TGFB1
29 neuroectodermal endocrine syndrome 10.0 CTGF SMAD2 SMAD3 SMAD7 TGFB1
30 gastrointestinal lymphoma 10.0 ACE AQP2 REN
31 idiopathic panuveitis 10.0 ACE ROBO2 SOX17 TGFB1
32 hypertrichosis of eyelid 10.0 ACE CCL2 CTGF TGFB1
33 malignant neoplasm of acoustic nerve 10.0 CCL2 CTGF SERPINE1 TGFB1
34 testicular lymphoma 10.0 ACE CTGF TGFB1
35 hypothyroidism, congenital nongoitrous, 5 10.0 ACE REN
36 calcinosis 9.8 ACE AQP2 CCL2 CTGF REN TGFB1
37 body dysmorphic disorder 9.8 ACE CCL2 REN SERPINE1
38 allergic bronchopulmonary aspergillosis 9.8 C16orf58 CCL2 MCU
39 brain injury 9.8 C16orf58 MCU UPK3A
40 systolic heart failure 9.8 ACE PAX2 ROBO2 SOX17 TGFB1 UPK3A
41 autoimmune-related retinopathy and optic neuropathy 9.8 ACE CCL2 SERPINE1 TGFB1
42 pyrimidine metabolic disorder 9.8 ACE CCL2 REN SERPINE1
43 budd-chiari syndrome 9.8 ACE BMP7 REN SERPINE1
44 sydenham chorea 9.7 ACE REN SERPINE1 TGFB1
45 pericarditis 9.7 ACE CCL2 REN SERPINE1
46 acute necrotizing encephalitis 9.5 AQP2 BMP7 CCL2 CDH1 CTGF REN
47 hemorrhagic cystitis 9.3 BMP7 CCL2 CDH1 CTGF REN SERPINE1
48 pulmonary valve insufficiency 7.9 ACE AQP2 BMP7 C16orf58 CCL2 CDH1

Graphical network of the top 20 diseases related to Ureteral Disease:



Diseases related to Ureteral Disease

Symptoms & Phenotypes for Ureteral Disease

MGI Mouse Phenotypes related to Ureteral Disease:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.38 ACE BMP7 CDH1 CTGF MCU PAX2
2 growth/size/body region MP:0005378 10.29 ACE AQP2 BMP7 CDH1 CTGF MCU
3 homeostasis/metabolism MP:0005376 10.28 ROBO2 SERPINE1 SMAD2 SMAD3 SMAD7 SOX17
4 behavior/neurological MP:0005386 10.25 BMP7 MCU REN ROBO2 SMAD2 SMAD3
5 mortality/aging MP:0010768 10.2 ACE AQP2 BMP7 CDH1 CTGF MCU
6 digestive/alimentary MP:0005381 10.18 SMAD3 SMAD7 SOX17 TGFB1 BMP7 CDH1
7 embryo MP:0005380 10.16 SOX17 TGFB1 BMP7 CDH1 CTGF PAX2
8 hematopoietic system MP:0005397 10.16 ACE AQP2 BMP7 REN SERPINE1 SMAD2
9 endocrine/exocrine gland MP:0005379 10.15 SMAD7 SOX17 TGFB1 ACE BMP7 CDH1
10 immune system MP:0005387 10.14 SMAD3 SMAD7 SOX17 TGFB1 ACE BMP7
11 integument MP:0010771 10.02 AQP2 BMP7 CDH1 CTGF SERPINE1 SMAD2
12 normal MP:0002873 9.76 BMP7 CDH1 CTGF REN ROBO2 SMAD2
13 neoplasm MP:0002006 9.73 ACE CDH1 SERPINE1 SMAD2 SMAD3 TGFB1
14 renal/urinary system MP:0005367 9.65 BMP7 PAX2 REN ROBO2 SERPINE1 SMAD3
15 reproductive system MP:0005389 9.4 ACE AQP2 BMP7 CDH1 PAX2 REN

Drugs & Therapeutics for Ureteral Disease

Drugs for Ureteral Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 295)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2 106133-20-4 129211
2
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
3
Alfuzosin Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 81403-80-7 2092
4
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
7
Silodosin Approved Phase 4,Phase 3,Phase 2 160970-54-7
8
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
9
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
10
Desflurane Approved Phase 4 57041-67-5 42113
11
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
12
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
13
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3 67-20-9 5353830
14
Sulfamethoxazole Approved Phase 4,Phase 3 723-46-6 5329
15
Trimethoprim Approved, Vet_approved Phase 4,Phase 3 738-70-5 5578
16
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
17
Mirabegron Approved Phase 4,Phase 2 223673-61-8
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
19
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3 58-05-9 54575, 6560146 143
20 Adrenergic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
21 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
22 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
23 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Early Phase 1
25 Antihypertensive Agents Phase 4,Phase 3,Phase 2
26 calcium channel blockers Phase 4,Phase 3
27 Calcium, Dietary Phase 4,Phase 3
28 Naftopidil Phase 4,Phase 3 57149-07-2
29 Platelet Aggregation Inhibitors Phase 4,Phase 3
30 Adjuvants, Immunologic Phase 4,Phase 2,Phase 1
31 Protective Agents Phase 4,Phase 3,Phase 2,Early Phase 1
32 Viscosupplements Phase 4
33 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antitubercular Agents Phase 4,Phase 3,Early Phase 1
37 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
38 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2
39 Analgesics, Opioid Phase 4,Phase 3
40 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 1
42 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
44 Cyclooxygenase Inhibitors Phase 4
45 Ketorolac Tromethamine Phase 4
46 Narcotics Phase 4,Phase 3
47 Nefopam Phase 4
48 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Anesthetics Phase 4,Phase 3,Phase 2
50 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 297)
id Name Status NCT ID Phase
1 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction Unknown status NCT01788865 Phase 4
2 Efficacy of Tamsulosin Oral-controlled Absorption System (OCAS) in the Treatment of Distal Ureteral Stones Unknown status NCT01167062 Phase 4
3 The Use of Medical-Expulsive Therapy With Alfuzocine xl 10mg x1/d for Distal Ureterolithiasis.a Randomized Prospective Study Unknown status NCT00489112 Phase 4
4 Naftopidil 75mg for Improving Clearance of Urinary Stones Unknown status NCT02011737 Phase 4
5 A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children Unknown status NCT02271035 Phase 4
6 Quality of Life in Patients With Double Loop Ureteral Stent (JJ Silicone Hydrogel Study) Unknown status NCT02489656 Phase 4
7 Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection Unknown status NCT00156546 Phase 4
8 The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones Unknown status NCT00451061 Phase 4
9 Efficacy of Nefopam and Morphine in Balanced Analgesia for Acute Ureteric Colic Unknown status NCT01543165 Phase 4
10 Functional MR Urography Completed NCT00301470 Phase 4
11 Nefopam and Morphine Consumption in the Treatment of Ureteral Calculi Completed NCT00639574 Phase 4
12 Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones Completed NCT01533389 Phase 4
13 Tamsulosin for Urolithiasis in the Emergency Dept Completed NCT00382265 Phase 4
14 Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms Completed NCT01381120 Phase 4
15 Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females Completed NCT01310582 Phase 4
16 A Randomized Controlled Trial on Antibiotic Prophylaxis in Children With Vesico-Ureteral Reflux Completed NCT00382343 Phase 4
17 Efficacy Study of Different Analgesic Options in Kidney Stone Pain Management Completed NCT02187614 Phase 4
18 Treatment of Upper Ureteric Stones Recruiting NCT02469766 Phase 4
19 Ureteral Stent-related Pain and Mirabegron (SPAM) Trial Recruiting NCT02095665 Phase 4
20 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Active, not recruiting NCT01741454 Phase 4
21 Phosphodiesterase 5 Inhibitors (PDE5i) (Sildenafil) as Medical Expulsive Therapy in Distal Ureteral Stones Active, not recruiting NCT02519153 Phase 4
22 Clinical Study of the Aorta-femoral Bypass and Hybrid Intervention and the Iliac Arteries With Stenting and Plasty of the Common Femoral Artery Effectiveness in Patients With the Iliac Segment and Femoral Artery Occlusive Disease (TASC C, D) Active, not recruiting NCT02580084 Phase 4
23 Silodosin Versus Tamsulosin for Treatment of Ureteral Stones Terminated NCT02369744 Phase 4
24 Use of a Ureteral Access Sheath During Ureteroscopy and Its Effect on Stone Free Rate Terminated NCT00199524 Phase 4
25 Celecoxib (Celebrex) in the Management of Acute Renal Colic Withdrawn NCT00304317 Phase 4
26 Alfuzosin for Medical Expulsion Therapy of Ureteral Stones Unknown status NCT00713739 Phase 3
27 Phase III Study of Chondrocyte Alginate Gel Suspension in Pediatric Patients With Vesicoureteral Reflux Unknown status NCT00004487 Phase 3
28 Extracorporeal Shock Wave Lithotriptor Indicated for Fragmenting Urinary Stones in the Kidney Unknown status NCT00959153 Phase 3
29 Evaluation of Tamsulosin in the Treatment of Ureteral Stones Completed NCT00151567 Phase 3
30 Medical Expulsive Therapy for Ureter Stone Using Naftopidil Completed NCT01952314 Phase 3
31 Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi Completed NCT00177086 Phase 3
32 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3
33 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3
34 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3
35 The Effect of Naftopidil for the Double-J Stent Discomfort Completed NCT01959074 Phase 3
36 The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms Completed NCT01530243 Phase 2, Phase 3
37 Anticholinergic vs. Botox Comparison Study Completed NCT01166438 Phase 3
38 Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) Completed NCT00405704 Phase 3
39 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
40 A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) Recruiting NCT01993979 Phase 3
41 Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract Recruiting NCT02021006 Phase 3
42 The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study Recruiting NCT02793128 Phase 3
43 Evaluation of the Efficiency of Autologous Adipocytes Graft in Endoscopic Treatment in Vesico-Renal Reflux in Children Recruiting NCT00367159 Phase 3
44 Radical Versus Simple Hysterectomy and Pelvic Node Dissection in Patients With Low-risk Early Stage Cervical Cancer (SHAPE) Recruiting NCT01658930 Phase 3
45 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3
46 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting NCT02426125 Phase 3
47 Randomization of Botox for Stent Pain and Irritative Voiding Symptoms Terminated NCT02078895 Phase 3
48 Effectiveness of Silodosin in Medical Expulsive Therapy for Ureteral Pelvic Stone From 4 to 10 mm. Terminated NCT02090439 Phase 3
49 Over Active Bladder Instillation Study - Botox Terminated NCT00667095 Phase 3
50 Refractory Urge Incontinence and Botox Injections Terminated NCT00373789 Phase 3

Search NIH Clinical Center for Ureteral Disease

Cochrane evidence based reviews: ureteral diseases

Genetic Tests for Ureteral Disease

Anatomical Context for Ureteral Disease

MalaCards organs/tissues related to Ureteral Disease:

39
Testes, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Ureteral Disease:

18
The Ureter

Publications for Ureteral Disease

Articles related to Ureteral Disease:

id Title Authors Year
1
Extensive dilation of distal ureter for endoscopic treatment of large volume ureteral disease. ( 7869503 )
1995
2
Ureteroscopy with rigid instruments in the management of distal ureteral disease. ( 6737571 )
1984
3
Ipsilateral ureteroureterostomy for single ureteral disease in patients with ureteral duplication: a review of 8 years of experience with 16 patients. ( 650746 )
1978
4
Role of the excretory urogram in the diagnosis of renal and ureteral disease. ( 4479909 )
1974
5
Transureteroureterostomy in the management of distal ureteral disease. ( 5047409 )
1972

Variations for Ureteral Disease

Expression for Ureteral Disease

Search GEO for disease gene expression data for Ureteral Disease.

Pathways for Ureteral Disease

Pathways related to Ureteral Disease according to GeneCards Suite gene sharing:

(show all 33)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.48 BMP7 CCL2 CDH1 CTGF SMAD2 SMAD3
2
Show member pathways
12.97 ACE BMP7 CCL2 CTGF REN TGFB1
3
Show member pathways
12.85 ACE CCL2 SERPINE1 SMAD2 SMAD3 TGFB1
4
Show member pathways
12.46 BMP7 SMAD2 SMAD3 SOX17 TGFB1
5
Show member pathways
12.4 BMP7 SMAD2 SMAD3 TGFB1
6 12.29 CDH1 SMAD2 SMAD3 TGFB1
7
Show member pathways
12.28 CDH1 SMAD2 SMAD3 TGFB1
8
Show member pathways
12.24 SERPINE1 SMAD2 SMAD3 SMAD7 TGFB1
9 12.17 BMP7 PAX2 SERPINE1 SMAD2 SMAD3 TGFB1
10 12.12 CDH1 SMAD2 SMAD3 TGFB1
11 12.03 CDH1 CTGF SERPINE1 SMAD2 SMAD3
12 12.01 SMAD2 SMAD3 SMAD7 TGFB1
13 11.87 CCL2 SERPINE1 SMAD2 SMAD3 TGFB1
14 11.85 SMAD2 SMAD3 SMAD7 TGFB1
15
Show member pathways
11.84 SMAD2 SMAD3 TGFB1
16
Show member pathways
11.8 SMAD2 SMAD3 TGFB1
17 11.78 BMP7 SMAD2 SMAD3 SMAD7 TGFB1
18 11.76 CCL2 REN TGFB1
19
Show member pathways
11.72 ACE REN TGFB1
20 11.71 SERPINE1 SMAD2 SMAD3 SMAD7
21
Show member pathways
11.7 SMAD2 SMAD3 TGFB1
22
Show member pathways
11.66 SMAD2 SMAD3 SMAD7 TGFB1
23 11.65 CDH1 SMAD2 SMAD3
24 11.64 BMP7 SMAD2 SMAD3 TGFB1
25 11.62 SERPINE1 SMAD2 SMAD3 SMAD7 TGFB1
26 11.52 BMP7 CCL2 CTGF SMAD7 TGFB1
27
Show member pathways
11.42 SMAD2 SMAD3 TGFB1
28 11.41 BMP7 CDH1 CTGF SERPINE1 SMAD2 SMAD3
29 11.32 SERPINE1 SMAD2 SMAD3 SMAD7 TGFB1
30 11.22 SMAD2 SMAD3 TGFB1
31 11.1 CTGF SERPINE1 SMAD2 SMAD3
32 11.06 CTGF SMAD2 SMAD3 SMAD7 TGFB1
33 10.81 CDH1 SMAD2 SMAD3 TGFB1

GO Terms for Ureteral Disease

Cellular components related to Ureteral Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 ACE BMP7 CCL2 CDH1 CTGF EDA
2 catenin complex GO:0016342 9.26 CDH1 SMAD7
3 transcription factor complex GO:0005667 9.26 SMAD2 SMAD3 SMAD7 SOX17
4 SMAD protein complex GO:0071141 9.16 SMAD2 SMAD3
5 SMAD2-SMAD3 protein complex GO:0071144 8.62 SMAD2 SMAD3

Biological processes related to Ureteral Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 CTGF EDA SMAD2 SMAD3 SOX17 TGFB1
2 angiogenesis GO:0001525 9.98 CCL2 CTGF SERPINE1 SOX17
3 aging GO:0007568 9.95 CCL2 CTGF PAX2 TGFB1
4 response to estradiol GO:0032355 9.89 BMP7 CTGF TGFB1
5 response to organic substance GO:0010033 9.89 CDH1 REN TGFB1
6 BMP signaling pathway GO:0030509 9.87 BMP7 SMAD7 TGFB1
7 response to wounding GO:0009611 9.86 CCL2 CTGF TGFB1
8 response to glucose GO:0009749 9.85 CTGF SMAD2 TGFB1
9 cellular response to transforming growth factor beta stimulus GO:0071560 9.83 SMAD3 SMAD7 TGFB1
10 positive regulation of cell differentiation GO:0045597 9.81 BMP7 CTGF SOX17
11 positive regulation of epithelial to mesenchymal transition GO:0010718 9.8 SMAD2 SMAD3 TGFB1
12 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.8 SMAD2 SMAD3 SMAD7 TGFB1
13 mesoderm formation GO:0001707 9.79 BMP7 SMAD2 SMAD3
14 positive regulation of bone mineralization GO:0030501 9.79 BMP7 SMAD3 TGFB1
15 protein kinase B signaling GO:0043491 9.78 CCL2 PAX2 TGFB1
16 gastrulation GO:0007369 9.77 SMAD2 SMAD3 SOX17
17 embryonic pattern specification GO:0009880 9.77 BMP7 SMAD2 SMAD3
18 kidney development GO:0001822 9.77 ACE BMP7 REN ROBO2 UPK3A
19 SMAD protein signal transduction GO:0060395 9.76 BMP7 SMAD2 SMAD3 TGFB1
20 positive regulation of collagen biosynthetic process GO:0032967 9.73 CCL2 CTGF TGFB1
21 activin receptor signaling pathway GO:0032924 9.72 SMAD2 SMAD3
22 transforming growth factor beta receptor signaling pathway GO:0007179 9.72 CCL2 SMAD2 SMAD3 SMAD7 TGFB1
23 positive regulation of transcription factor import into nucleus GO:0042993 9.71 CDH1 SMAD3
24 endoderm formation GO:0001706 9.71 SMAD2 SOX17
25 negative regulation of cell-cell adhesion GO:0022408 9.71 CDH1 TGFB1
26 signal transduction involved in regulation of gene expression GO:0023019 9.71 SMAD2 SMAD3 SOX17
27 beta-amyloid metabolic process GO:0050435 9.7 ACE REN
28 pathway-restricted SMAD protein phosphorylation GO:0060389 9.7 SMAD7 TGFB1
29 lens fiber cell differentiation GO:0070306 9.7 SMAD3 TGFB1
30 negative regulation of wound healing GO:0061045 9.69 SERPINE1 SMAD3
31 angiotensin maturation GO:0002003 9.69 ACE REN
32 positive regulation of cell-cell adhesion GO:0022409 9.69 CCL2 SMAD7
33 salivary gland morphogenesis GO:0007435 9.68 BMP7 TGFB1
34 response to cholesterol GO:0070723 9.67 SMAD2 TGFB1
35 primary miRNA processing GO:0031053 9.67 SMAD2 SMAD3
36 pericardium development GO:0060039 9.67 SMAD2 SMAD3
37 response to laminar fluid shear stress GO:0034616 9.66 SMAD7 TGFB1
38 nodal signaling pathway GO:0038092 9.66 SMAD2 SMAD3
39 metanephric collecting duct development GO:0072205 9.65 AQP2 PAX2
40 mesonephros development GO:0001823 9.65 BMP7 PAX2 REN
41 common-partner SMAD protein phosphorylation GO:0007182 9.64 SMAD2 TGFB1
42 regulation of striated muscle tissue development GO:0016202 9.63 SMAD3 TGFB1
43 positive regulation of extracellular matrix assembly GO:1901203 9.63 SMAD3 TGFB1
44 embryonic foregut morphogenesis GO:0048617 9.61 SMAD2 SMAD3 SOX17
45 mononuclear cell proliferation GO:0032943 9.58 ACE TGFB1
46 paraxial mesoderm morphogenesis GO:0048340 9.58 SMAD2 SMAD3
47 SMAD protein complex assembly GO:0007183 9.58 SMAD2 SMAD3 TGFB1
48 evasion or tolerance of host defenses by virus GO:0019049 9.57 SMAD3 TGFB1
49 endoderm development GO:0007492 9.56 SMAD2 SMAD3 SOX17 TGFB1
50 regulation of binding GO:0051098 9.33 SMAD2 SMAD3 TGFB1

Molecular functions related to Ureteral Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.67 PAX2 SMAD3 SMAD7 SOX17
2 enhancer binding GO:0035326 9.46 SMAD2 SMAD3
3 beta-catenin binding GO:0008013 9.46 CDH1 SMAD3 SMAD7 SOX17
4 co-SMAD binding GO:0070410 9.43 SMAD2 SMAD3
5 I-SMAD binding GO:0070411 9.4 SMAD2 SMAD7
6 primary miRNA binding GO:0070878 9.32 SMAD2 SMAD3
7 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.26 SMAD2 SMAD3
8 type I transforming growth factor beta receptor binding GO:0034713 9.13 SMAD2 SMAD7 TGFB1
9 transforming growth factor beta receptor binding GO:0005160 8.92 BMP7 SMAD2 SMAD3 TGFB1

Sources for Ureteral Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....